Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

Recent Video and Audio from Zelira Therapeutics

Zelira Chairman Presentation at Cantor Fitzgerald International Cannabis Forum

Zelira Therapeutics Investor Presentation – Sept 2022

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

Zelira Therapeutics Investor Presentation

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.

Channel 7 News Perth

Zelira product helping young patient with autism spectrum disorder

Zelira AGM Presentation January 2022

CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022

Zelira Therapeutics’ commercialisation program

Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive

Channel 9 News Perth

Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain

Start typing and press Enter to search

Shopping Cart